Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHA:600613)
8.53
+0.43 (5.31%)
Sep 14, 2026, 3:00 PM CST
SHA:600613 Revenue
Shanghai Shenqi Pharmaceutical Investment Management had revenue of 425.19M CNY in the quarter ending June 30, 2026, a decrease of -11.59%. This brings the company's revenue in the last twelve months to 1.84B, down -3.14% year-over-year. In the year 2025, Shanghai Shenqi Pharmaceutical Investment Management had annual revenue of 1.95B, down -4.71%.
Revenue (ttm)
1.84B
Revenue Growth
-3.14%
P/S Ratio
2.20
Revenue / Employee
1.54M
Employees
1,196
Market Cap
4.04B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.95B | -96.44M | -4.71% |
| Dec 31, 2024 | 2.05B | -292.14M | -12.48% |
| Dec 31, 2023 | 2.34B | -47.67M | -2.00% |
| Dec 31, 2022 | 2.39B | 85.58M | 3.72% |
| Dec 31, 2021 | 2.30B | 484.03M | 26.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Pharmaceutical Group Company | 54.82B |
| Zhejiang Int'l Group | 34.20B |
| Zhejiang Zhenyuan Share | 1.86B |
| GuangYuYuan Chinese Herbal Medicine | 1.41B |
| Hangzhou Minsheng Healthcare | 854.51M |
| Chongqing Lummy Pharmaceutical | 748.94M |
| Hangzhou Bio-Sincerity Pharma-Tech | 709.72M |
| Hubei Guangji Pharmaceutical | 651.57M |